Skip to content
Back to AVLN

Avalyn Pharma Inc.

Open-market purchases and sales reported on SEC Forms 4 and 5, with each filing and its footnotes.

Since Nov 18, 2025
Transactions
8
Purchases
4
Sales
4
Purchase value
$20.00M
Sale value
$6.70M

Values are shares multiplied by reported price when both were supplied, each trade counted once however many filers reported it.

FMR LLC10% owner · See Remark 1
4
Filed Nov 12, 2026Period of report Nov 9, 20260001193125-26-457571
TransactionSecuritySharesPriceValueHeld afterOwnership
SaleNov 10, 2026
Common StockF35,565$29.56$164.50K2,103,970IndirectF-Prime Capital Partners Healthcare Fund V LP
SaleNov 10, 2026
Common StockF447,889$30.28$1.45M2,056,081IndirectF-Prime Capital Partners Healthcare Fund V LP
SaleNov 9, 2026
Common StockF1173,661$29.06$5.05M2,110,874IndirectF-Prime Capital Partners Healthcare Fund V LP
SaleNov 9, 2026
Common StockF21,339$29.75$39.84K2,109,535IndirectF-Prime Capital Partners Healthcare Fund V LP
Filing footnotes · 4
  1. F1The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.65 to $29.64. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  2. F2The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.68 to $29.83. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  3. F3The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $28.82 to $29.81. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
  4. F4The price reported for this transaction is the weighted average price of multiple trades at prices ranging from $29.82 to $30.62. FMR LLC hereby undertakes to provide upon request by the Commission staff, the issuer, or a security holder of the issuer full information.
Open on SEC EDGAR
Novo Holdings A/S10% owner
4
Filed May 5, 2026Period of report May 1, 20260001388325-26-000021
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 1, 2026
Voting Common Stock555,555$18.00$10.00M3,883,289Direct
Filing footnotes · 1
  1. F1The Series A Preferred Stock, Series B Preferred Stock, Series C-1 Preferred Stock, Series C-2 Preferred Stock and Series D Preferred Stock automatically converted into voting common stock upon the closing of the Issuer's initial public offering for no additional consideration, on a 1-for-19.2417 basis, and had no expiration date.
Open on SEC EDGAR
Jill CarrollDirector
4
Filed May 1, 2026Period of report May 1, 20260001193125-26-201894
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 1, 2026
Common StockF2277,778$18.00$5.00M2,186,562IndirectSee Note 2
Filing footnotes · 3
  1. F1On May 1, 2026, each share of Series C-1 Convertible Preferred Stock (the "Series C-1 Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had no expiration date.
  2. F2The securities are directly held by SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"). SR One Capital Partners II, LP ("SR One Partners II") serves as the general partner of SR One Fund II Aggregator, and SR One Capital Management, LLC serves as the general partner of SR One Partners II. The Reporting Person is a partner of SR One Capital Management, LP, an entity affiliated with SR One Fund II Aggregator, and a limited partner of SR One Partners II. The Reporting Person disclaims beneficial ownership of these securities for purposes of Section 16 of the Securities Exchange Act of 1934, as amended ("Section 16"), except to the extent of her pecuniary interest therein, if any, and this report shall not be deemed an admission that the Reporting Person is the beneficial owner of such securities for Section 16 or any other purpose.
  3. F3On May 1, 2026, each share of Series D Convertible Preferred Stock (the "Series D Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date.
Open on SEC EDGAR
George Simeon10% owner
SR One Capital Management, LLC10% owner
4
Filed May 1, 2026Period of report May 1, 20260001193125-26-201887
TransactionSecuritySharesPriceValueHeld afterOwnership
PurchaseMay 1, 2026
Common StockF2277,778$18.00$5.00M2,186,562IndirectSee Note 2
PurchaseMay 1, 2026
Common StockF4277,777$18.00$5.00M1,122,087IndirectSee Note 4
Filing footnotes · 4
  1. F1On May 1, 2026, each share of Series C-1 Convertible Preferred Stock (the "Series C-1 Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series C-1 Preferred Stock had no expiration date.
  2. F2The reported securities are held directly by SR One Capital Fund II Aggregator, LP ("SR One Fund II Aggregator"). SR One Capital Partners II, LP ("SR One Partners II") is the general partner of SR One Fund II, and SR One Capital Management, LLC ("SR One Capital Management") is the general partner of SR One Partners II. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One Partners II, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
  3. F3On May 1, 2026, each share of Series D Convertible Preferred Stock (the "Series D Preferred Stock") automatically converted into shares of Common Stock on a one-for-19.2417 basis without payment of further consideration immediately prior to the closing of the Issuer's initial public offering. The Series D Preferred Stock had no expiration date.
  4. F4The reported securities are held directly by AMZL, LP ("AMZL"). SR One Capital SMA Partners, LP ("SR One SMA Partners") is the general partner of AMZL, and SR One Capital Management is the general partner of SR One SMA Partners. Simeon George, M.D. is the managing member of SR One Capital Management. Each of SR One SMA Partners, SR One Capital Management and Dr. George may be deemed to have shared power to vote or dispose of these shares, and each disclaims beneficial ownership of the shares except to the extent of any pecuniary interest therein.
Open on SEC EDGAR

P and S transaction codes only. Grants, gifts, option exercises, tax withholding, and Form 144 notices are not counted as purchases or sales. A row whose filed price fails a plausibility check, or that is not common stock, is listed but left out of the values; a trade reported by several filers is counted once.